Skip to main navigation
Skip to search
Skip to main content
Northwestern Scholars Home
Help & FAQ
Home
Experts
Organizations
Research Output
Grants
Core Facilities
Research Data
Search by expertise, name or affiliation
Adjuvant endocrine therapy for early breast cancer: The story so far
William J. Gradishar
Medicine, Hematology Oncology Division
Research output
:
Contribution to journal
›
Review article
›
peer-review
12
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Adjuvant endocrine therapy for early breast cancer: The story so far'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Early Breast Cancer
100%
Aromatase Inhibitors
100%
Adjuvant Endocrine Therapy
100%
Clinical Trials
50%
Postmenopausal Women
50%
Distant Metastasis
50%
Early Recurrence
50%
Improved Survival
50%
Breast Cancer Recurrence
50%
Poor Survival
50%
Breast Cancer Mortality
50%
Metastatic Recurrence
50%
Two-peak
50%
Distant Recurrence
50%
Neoadjuvant Endocrine Therapy
50%
Recurrence Events
50%
Pharmacology, Toxicology and Pharmaceutical Science
Endocrine Therapy
100%
Breast Cancer
100%
Recurrent Disease
100%
Tamoxifen
75%
Aromatase Inhibitor
50%
Hormone Cancer Therapy
25%
Clinical Trial
25%
Cancer Mortality
25%
Nursing and Health Professions
Hormonal Therapy
100%
Breast Cancer
100%
Recurrent Disease
100%
Tamoxifen
75%
Aromatase Inhibitor
50%
Cancer Mortality
25%